MX2019011281A - Compuestos de dinucleotidos ciclicos modificados. - Google Patents

Compuestos de dinucleotidos ciclicos modificados.

Info

Publication number
MX2019011281A
MX2019011281A MX2019011281A MX2019011281A MX2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A MX 2019011281 A MX2019011281 A MX 2019011281A
Authority
MX
Mexico
Prior art keywords
cyclic dinucleotide
modified cyclic
dinucleotide compounds
compounds
modified
Prior art date
Application number
MX2019011281A
Other languages
English (en)
Inventor
Oost Thorsten
Fleck Martin
Carotta Sebastian
Andreas KUTTRUFF Christian
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019011281A publication Critical patent/MX2019011281A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Abstract

Compuestos de la Fórmula (I) (ver fórmula) en donde la Base1 y la Base2 como se definen en la reivindicación 1 son moduladores de STING.
MX2019011281A 2017-03-22 2018-03-16 Compuestos de dinucleotidos ciclicos modificados. MX2019011281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17162392 2017-03-22
PCT/EP2018/056656 WO2018172206A1 (en) 2017-03-22 2018-03-16 Modified cyclic dinucleotide compounds

Publications (1)

Publication Number Publication Date
MX2019011281A true MX2019011281A (es) 2019-11-01

Family

ID=58412904

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011281A MX2019011281A (es) 2017-03-22 2018-03-16 Compuestos de dinucleotidos ciclicos modificados.

Country Status (20)

Country Link
US (1) US10392419B2 (es)
EP (1) EP3601313B1 (es)
JP (2) JP6742534B2 (es)
KR (1) KR20190130612A (es)
CN (1) CN110382515B (es)
AR (1) AR111247A1 (es)
AU (1) AU2018239468A1 (es)
BR (1) BR112019017812A2 (es)
CA (1) CA3056008A1 (es)
CL (1) CL2019002590A1 (es)
CO (1) CO2019010023A2 (es)
EA (1) EA201992209A1 (es)
IL (1) IL268799A (es)
JO (1) JOP20190218A1 (es)
MX (1) MX2019011281A (es)
PE (1) PE20191556A1 (es)
PH (1) PH12019502155A1 (es)
SG (1) SG11201908567UA (es)
TW (1) TW201842919A (es)
WO (1) WO2018172206A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017161349A1 (en) 2016-03-18 2017-09-21 Immune Sensor, Llc Cyclic di-nucleotide compounds and methods of use
EP3475292A1 (en) * 2016-06-24 2019-05-01 Biogen MA Inc. Synthesis of thiolated oligonucleotides without a capping step
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
US11542293B2 (en) 2017-11-10 2023-01-03 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
CN111989338A (zh) * 2018-03-27 2020-11-24 勃林格殷格翰国际有限公司 修饰的环二核苷酸化合物
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2020117624A1 (en) * 2018-12-07 2020-06-11 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
EP3891165A4 (en) * 2018-12-07 2022-08-24 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
US20220033431A1 (en) * 2018-12-07 2022-02-03 Merck Sharp & Dohme Corp. Cyclic Di-Nucleotide Compounds as STING Agonists
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP3966222A4 (en) 2019-05-09 2023-10-04 Aligos Therapeutics, Inc. MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS
CN114173824A (zh) 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
AU2020310853A1 (en) 2019-07-05 2022-01-27 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
CA3157192A1 (en) * 2019-10-07 2021-04-15 The General Hospital Corporation Compositions and methods for pulmonary surfactant-biomimetic nanoparticles
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
US20220111028A1 (en) 2020-10-14 2022-04-14 Boehringer Ingelheim International Gmbh Combination Of A STING Agonist And A Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1729781B1 (en) 2004-03-15 2012-10-24 Karaolis, David K. R. A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP2591001B1 (en) 2010-07-09 2021-11-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to cd27
BR112015013440B1 (pt) * 2012-12-13 2020-12-08 Aduro Biotech, Inc composições compreendendo dinucleotídeos de purina cíclicos com estereoquímicas
PL2934598T3 (pl) 2012-12-19 2018-10-31 Board Of Regents, The University Of Texas System Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR112016018408A2 (pt) 2014-03-14 2017-12-26 Immutep Sas moléculas de anticorpo à lag-3 e usos das mesmas
PE20170198A1 (es) 2014-06-04 2017-04-08 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting
EP3546473A1 (en) 2014-12-16 2019-10-02 Kayla Therapeutics Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JO3746B1 (ar) * 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
WO2017027645A1 (en) 2015-08-13 2017-02-16 Merck Sharp & Dohme Corp. Cyclic di-nucleotide compounds as sting agonists
WO2018009466A1 (en) * 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20190218A1 (ar) * 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة

Also Published As

Publication number Publication date
BR112019017812A2 (pt) 2020-03-31
CN110382515B (zh) 2023-03-03
CA3056008A1 (en) 2018-09-27
SG11201908567UA (en) 2019-10-30
PH12019502155A1 (en) 2020-07-06
EA201992209A1 (ru) 2020-03-16
EP3601313A1 (en) 2020-02-05
AR111247A1 (es) 2019-06-19
TW201842919A (zh) 2018-12-16
CL2019002590A1 (es) 2020-01-24
JP6742534B2 (ja) 2020-08-19
CN110382515A (zh) 2019-10-25
EP3601313B1 (en) 2021-03-10
PE20191556A1 (es) 2019-10-24
JOP20190218A1 (ar) 2019-09-22
KR20190130612A (ko) 2019-11-22
JP2020514389A (ja) 2020-05-21
US10392419B2 (en) 2019-08-27
US20180273578A1 (en) 2018-09-27
WO2018172206A1 (en) 2018-09-27
AU2018239468A1 (en) 2019-09-12
JP2020203887A (ja) 2020-12-24
CO2019010023A2 (es) 2019-09-30
IL268799A (en) 2019-10-31

Similar Documents

Publication Publication Date Title
PH12019502155A1 (en) Modified cyclic dinucleotide compounds
PH12019500706A1 (en) Cyclic dinucleotide compounds
PH12019502870A1 (en) Small molecule modulators of human sting
ZA201805009B (en) Stable inoculant compositions and methods for producing same
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
PH12015501720A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
ZA201507627B (en) P2x7 modulators
UY36949A (es) 2,4-dihidroxi-nicotinamidas como agonistas de apj
GB2547402A (en) Prevention and treatment of microbial infections
PH12019502646A1 (en) Pyrazole magl inhibitors
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
MX2020002611A (es) Activador especifico de akt3 y usos del mismo.
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
MX2017010357A (es) Derivados novedosos de n-acil-arilsulfonamida como inhibidores de aminoacil acido ribonucleico de transferencia (arnt) sintetasa.
WO2018237010A3 (en) VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE
MX2022007179A (es) Compuestos heterociclicos funcionalizados como moduladores del estimulador de genes de interferon.
MX2018007468A (es) Composiciones de colageno 7 y metodos para usar las mismas.
MX2016012314A (es) Analagos de apelina ciclicos.
PH12018501585B1 (en) Novel pyrrolidine derivatives
WO2018022844A3 (en) COMPOSITIONS AND METHODS FOR MODULATION OF FACTOR IX FUNCTION
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.
WO2019028012A3 (en) METHODS OF USING PEMBROLIZUMAB AND TREBANANIB
MY173966A (en) A cell-based composition and use thereof for treatment of acute stroke
MY171690A (en) A cell-based composition and use thereof for treatment of end-stage ischemic cardiomyopathy
MY176109A (en) A cell-based composition and use thereof for treatment of critical limb ischemia